Promyelinating drugs promote functional recovery in an autism spectrum disorder mouse model of Pitt–Hopkins syndrome
Brain · 01.08.2023 · 146 (8) · 3331-3346
DOI: 10.1093/brain/awad057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 18.04.2023. Verfasst von Joseph F Bohlen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA. Hauptthemen laut MEDLINE: Intellectual Disability, Autism Spectrum Disorder. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIMH NIH HHS, Pitt–Hopkins Research Foundation.
Abstract (Originalsprache)
Pitt–Hopkins syndrome is an autism spectrum disorder caused by autosomal dominant mutations in the human transcription factor 4 gene (TCF4). One pathobiological process caused by murine Tcf4 mutation is a cell autonomous reduction in oligodendrocytes and myelination. In this study, we show that the promyelinating compounds, clemastine, sobetirome and Sob-AM2 are effective at restoring myelination defects in a Pitt–Hopkins syndrome mouse model. In vitro, clemastine treatment reduced excess oligodendrocyte precursor cells and normalized oligodendrocyte density. In vivo, 2-week intraperitoneal administration of clemastine also normalized oligodendrocyte precursor cell and oligodendrocyte density in the cortex of Tcf4 mutant mice and appeared to increase the number of axons undergoing myelination, as EM imaging of the corpus callosum showed a significant increase in the proportion of uncompacted myelin and an overall reduction in the g-ratio. Importantly, this treatment paradigm resulted in functional rescue by improving electrophysiology and behaviour. To confirm behavioural rescue was achieved via enhancing myelination, we show that treatment with the thyroid hormone receptor agonist sobetirome or its brain penetrating prodrug Sob-AM2, was also effective at normalizing oligodendrocyte precursor cell and oligodendrocyte densities and behaviour in the Pitt–Hopkins syndrome mouse model. Together, these results provide preclinical evidence that promyelinating therapies may be beneficial in Pitt–Hopkins syndrome and potentially other neurodevelopmental disorders characterized by dysmyelination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA.
- Department of Physiology and Neurobiology, University of Connecticut, Storrs, CT 06269, USA.
- Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Department of Physiology & Pharmacology and Program in Chemical Biology, Oregon Health & Science University, Portland, OR 97239, USA.
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
ORCID-Profile: Srinidhi Rao Sripathy
Förderung
- NHLBI NIH HHS
- NIMH NIH HHS
- Pitt–Hopkins Research Foundation
- NIMH
Zitieren
APA
Bohlen, J. F., Cleary, C. M., Das, D., Sripathy, S. R., Sadowski, N., Shim, G., Kenney, R. F., Buchler, I. P., Banerji, T., Scanlan, T. S., Mulkey, D. K., & Maher, B. J. (2023). Promyelinating drugs promote functional recovery in an autism spectrum disorder mouse model of Pitt–Hopkins syndrome. Brain, 146(8), 3331-3346. https://doi.org/10.1093/brain/awad057
Vancouver
Bohlen JF, Cleary CM, Das D, Sripathy SR, Sadowski N, Shim G, et al. Promyelinating drugs promote functional recovery in an autism spectrum disorder mouse model of Pitt–Hopkins syndrome. Brain. 2023;146(8):3331-3346. doi:10.1093/brain/awad057
BibTeX
@article{Bohlen2023,
author = {Bohlen, Joseph F and Cleary, Colin M and Das, Debamitra and Sripathy, Srinidhi Rao and Sadowski, Norah and Shim, Gina and Kenney, Rakaia F and Buchler, Ingrid P and Banerji, Tapasree and Scanlan, Thomas S and Mulkey, Daniel K and Maher, Brady J},
title = {Promyelinating drugs promote functional recovery in an autism spectrum disorder mouse model of Pitt–Hopkins syndrome},
journal = {Brain},
year = {2023},
volume = {146},
number = {8},
pages = {3331--3346},
doi = {10.1093/brain/awad057}
}
EUVIMED